About BigHat Biosciences
BigHat Biosciences focuses on developing antibody therapies using machine learning and synthetic biology. Their main product is the Milliner platform, which integrates a wet lab with advanced machine learning to rapidly design and engineer antibodies. This platform enables the synthesis, purification, and characterization of hundreds of antibodies each week, allowing for quicker and more effective treatment options for challenging diseases like certain infections and cancers. Unlike many competitors, BigHat emphasizes a balance between high performance and a supportive work culture. The company's goal is to create safer and more effective therapies for patients while maintaining a family-friendly environment.
San Carlos, CaliforniaHeadquarters
2019Year Founded
$96.6MTotal Funding
SERIES_BCompany Stage
AI & Machine Learning, BiotechnologyIndustries
51-200Employees
Risks
Increased ADC competition may overshadow BigHat's collaborations, affecting market position.
Biotech market volatility poses risks to BigHat's expansion despite current growth.
Substantial funding needs highlight financial risks if future rounds fall short.
Differentiation
BigHat's Milliner platform integrates AI with synthetic biology for rapid antibody development.
The company focuses on difficult-to-treat diseases, enhancing treatment options for complex conditions.
BigHat's strategic collaborations with industry leaders like Janssen and Merck boost its innovation.
Upsides
AI-driven protein engineering is crucial for personalized medicine, benefiting BigHat's platform.
Recent ADC advancements open new cancer treatment avenues, aligning with BigHat's focus.
BigHat's collaborations with AI firms lead to innovative drug development solutions.
Funding
Total raised$96.59 M
Latest valuation$375.00 M
StageSERIES_B
SERIES A
1/31/2021$19
$95.00 MSEED
11/30/2019$5
$26.50 M